Progyny (NASDAQ:PGNY) Releases FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 1.520-1.620 for the period, compared to the consensus EPS estimate of 1.660. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q1 2025 guidance to 0.440-0.470 EPS.

Progyny Stock Performance

PGNY traded down $0.53 during trading on Monday, hitting $22.00. The stock had a trading volume of 3,660,909 shares, compared to its average volume of 1,537,778. The stock has a 50 day simple moving average of $20.83 and a two-hundred day simple moving average of $18.67. Progyny has a twelve month low of $13.39 and a twelve month high of $38.98. The company has a market capitalization of $1.87 billion, a PE ratio of 37.93, a PEG ratio of 2.39 and a beta of 1.34.

Analyst Ratings Changes

Several research analysts recently weighed in on PGNY shares. Barclays dropped their target price on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Truist Financial restated a "hold" rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Bank of America boosted their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group upped their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research note on Friday. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $24.82.

Remove Ads

Insider Transactions at Progyny

In related news, Chairman David J. Schlanger acquired 150,000 shares of the firm's stock in a transaction dated Thursday, December 26th. The stock was acquired at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This represents a 191.65 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Peter Anevski bought 209,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.